ArticleFrontiers in medicine2026
Artificial intelligence for rapid on-site evaluation of lymph node fine-needle aspiration: improving diagnostic efficiency and accuracy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymphadenopathy may result from inflammation, tuberculosis, or tumors, with lymph node status being a key prognostic indicator. Early accurate differentiation of benign and malignant lesions is therefore vital for clinical management. Although imaging offers adjunctive information, histopathology and cytology on biopsy specimens remain the gold standard, albeit with a 2-4 day turnaround. CT-guided biopsy ensures precise sampling, but final diagnosis depends on pathology. AI-ROSE is an emerging real-time cytological tool that can rapidly classify lesions and guide sampling/treatment decisions. While well-validated in lung biopsy, its role in lymph node biopsy is less studied, as most AI research emphasizes imaging over cytology. Therefore, this study assessed the clinical value and diagnostic concordance of AI-ROSE, providing a reference for intraoperative rapid diagnosis and specimen adequacy evaluation. Methods: This study included 54 patients who underwent lymph node biopsy from June 2024 to June 2026. All samples were obtained by percutaneous puncture under CT guidance and simultaneously underwent AI-ROSE analysis, exfoliative cytology examination, and histopathological examination. Using the histopathological results as the gold standard, the sensitivity, specificity, positive/negative predictive values, and accuracy of AI-ROSE and exfoliative cytology methods were calculated separately, and the consistency between the methods and histopathological diagnosis was analyzed. Results: The sensitivity of the AI-ROSE diagnosis was 90.48% (95% CI: 77.9% - 96.2%), and the diagnostic accuracy was 89.80% (95% CI: 78.2% - 95.6%). Both of these indicators were higher than those of the exfoliative cytology examination. The consistency between AI-ROSE and the pathological gold standard was moderate ( Conclusion: In this study, AI-ROSE showed higher sensitivity and diagnostic accuracy than traditional exfoliative cytology for lymph node biopsy. As a practical adjunctive tool, it offers real-time guidance on specimen adequacy and the need for repeat puncture, thereby streamlining the diagnostic process. Notably, AI-ROSE findings should be used as supplementary references and must not replace final histopathological diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.